Im vergangenen Jahr erzielte BioMarin Pharmaceutical Inc für sein leistungsstärkstes Segment, Voxzogo, Einnahmen von 926.92M USD. Die Region United States leistete den größten Beitrag mit 1.10B USD im letzten Jahr. Im letzten Quartal berichtete BioMarin Pharmaceutical Inc über Einnahmen in Höhe von 252.53M USD für den Zeitraum bis zum 2026-06-30, die aus dem leistungsstärksten Segment, Voxzogo, stammten. United States trug mit 371.07M USD den höchsten Umsatz bei.

Nach Geschäftsbereich

Umsatz

Anteil

Jährlich

Jährlich

Vierteljährlich

Voxzogo

Vimizim

Naglazyme

Palynziq

Aldurazyme

Brineura

Kuvan

Royalty and other revenue

Roctavian

Firdapse

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

Voxzogo

926.92M(28.78%)

735.09M(25.76%)

469.88M(19.42%)

169.13M(8.28%)

5.86M(0.33%)

--(--)

Vimizim

792.05M(24.59%)

739.78M(25.92%)

701.05M(28.98%)

663.74M(32.50%)

623.14M(34.94%)

544.26M(30.14%)

544.35M(32.77%)

481.98M(32.78%)

Naglazyme

485.40M(15.07%)

479.58M(16.80%)

420.29M(17.37%)

443.79M(21.73%)

380.45M(21.33%)

391.30M(21.67%)

374.33M(22.54%)

345.85M(23.52%)

Palynziq

433.31M(13.45%)

355.05M(12.44%)

303.92M(12.56%)

255.03M(12.49%)

237.47M(13.32%)

170.98M(9.47%)

86.86M(5.23%)

12.17M(0.83%)

Aldurazyme

208.51M(6.47%)

183.89M(6.44%)

131.25M(5.43%)

128.42M(6.29%)

122.77M(6.88%)

130.11M(7.20%)

97.81M(5.89%)

135.10M(9.19%)

Brineura

186.40M(5.79%)

169.08M(5.92%)

161.89M(6.69%)

154.33M(7.56%)

128.03M(7.18%)

110.19M(6.10%)

72.00M(4.33%)

39.89M(2.71%)

Kuvan

99.53M(3.09%)

120.90M(4.24%)

180.77M(7.47%)

227.58M(11.14%)

285.78M(16.02%)

457.74M(25.35%)

463.35M(27.90%)

433.58M(29.49%)

Royalty and other revenue

53.49M(1.66%)

44.47M(1.56%)

46.69M(1.93%)

--(--)

Roctavian

35.64M(1.11%)

26.07M(0.91%)

3.49M(0.14%)

--(--)

Firdapse

--(--)

1.29M(0.07%)

22.35M(1.35%)

21.79M(1.48%)

Nach Region

Umsatz

Anteil

Jährlich

Jährlich

Vierteljährlich

United States

Europe

Rest of the world

Latin America

ALDURAZYME net product revenues marked by Sanofi

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

United States

1.10B(34.88%)

924.81M(32.92%)

771.31M(32.51%)

684.28M(35.76%)

657.70M(36.88%)

912.38M(49.04%)

778.44M(45.68%)

696.79M(46.73%)

Europe

874.33M(27.60%)

829.03M(29.51%)

669.33M(28.21%)

650.95M(34.02%)

558.95M(31.34%)

518.47M(27.87%)

509.19M(29.88%)

436.43M(29.27%)

Rest of the world

544.47M(17.19%)

493.63M(17.57%)

468.21M(19.73%)

311.57M(16.28%)

375.69M(21.07%)

223.75M(12.03%)

197.63M(11.60%)

172.94M(11.60%)

Latin America

435.48M(13.75%)

378.08M(13.46%)

332.44M(14.01%)

266.80M(13.94%)

191.15M(10.72%)

205.86M(11.07%)

218.79M(12.84%)

185.05M(12.41%)

ALDURAZYME net product revenues marked by Sanofi

208.51M(6.58%)

183.89M(6.55%)

131.25M(5.53%)

--(--)